why choose us

First received: May 26, 2023

Clinical Trial: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Study Status: Completed

Recruit Status: RECRUITING

Condition: Malaria

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Dose Escalation, Double Blind, Placebo Controlled Clinical Trial With Controlled Human Malaria Infections (CHMI) to Evaluate Safety, Tolerability, Pharmacokinetics, and Protective Efficacy

Brief Summary: This is a First-in-Human (FiH) double-blind, randomized, placebo-controlled, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP).This study will evaluate the safety, tolerability, pharmacokinetics (PK), and protective efficacy of MAM01, as well as safety and PK of repeat subcutaneous (SC) dosing.

Read more